Hoffmann-la Roche Inc.

Roche Palo Alto LLC

F. Hoffmann-la Roche Ag

Henner Knust

Matthias Heinrich Nettekoven

Andrew William Thomas

Bernd Buettelmann

Hasane Ratni

Emmanuel Pinard

Claus Riemer

Mark Rogers-Evans

Olivier Roche

Luca Claudio Gobbi

Roland Jakob-Roetne

Bo Han

Anja Limberg

Philippe Jablonski

Matthias Koerner

Andreas Koblet

Dieter Muri

Matthew C Lucas

Walter Vifian

Xihan Wu

Caterina Bissantz

Parichehr Malherbe

Kenichi Kawasaki

Edilio Borroni

Michael Honer

Heinz Stadler

Katrin Groebke Zbinden

Simona Maria Ceccarelli

Giuseppe Cecere

Maria-Clemencia Hernandez

Angelique Patiny-Adam

Carine Guerot

Bernd Kuhn

Georg Jaeschke

Peter Mohr

Synese Jolidon

Johannes Aebi

Alexander Flohr

Jean-Marc Plancher

Torsten Hoffmann

Luke Green

Hans Peter Maerki

Thomas Luebbers

Benoit Hornsperger

Kurt E Amrein

Lothar Lindemann

Erwin Goetschi

Xuefei Tan

Yongfu Liu

Mingwei Zhou

Fionn O'Hara

Bernhard Fasching

Barbara Biemans

Sandra Steiner

Valerie Runtz-Schmitt

Karlheinz Baumann

Alexander V Mayweg

Jiaqiang Dong

Angélique Patiny-Adam

Andres Miguel Olivares Morales

Roetne Roland Jakob

The present invention provides new arylsulfonamide compounds having the general formula (I) wherein L, R, R, Rand Rare as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.

Arylsulfonamide derivatives

The invention provides novel compounds having the general formula (I) or (II) wherein R, R, R, R, W, Y and Z are as described herein, compositions including the compounds and methods of using the compounds.

Isoxazolyl ether derivatives as GABA&#x3b1;5 PAM

The invention relates to small molecule imaging tools, specifically compounds of formula II and to pharmaceutically acceptable acid addition salts thereof, wherein R-Rhave any of the values defined in the specification.

2-hetaryl imidazol[1,2-a]pyridine derivatives

Compounds having the formula (I) wherein R, R, R, R, R, R, X, Y and Z are as described herein, compositions including the compounds and methods of using the compounds.

The present invention relates to compounds that may be used for binding and imaging tau aggregates and related beta-sheet aggregates including, besides others, beta-amyloid aggregates or alpha-synuclein aggregates.

Diazacarbazole derivatives as tau-PET-ligands

The invention relates to small molecule imaging tools.

Imaging methods using 2-hetaryl imidazol[1,2-a]pyridine derivatives

The invention relates to compounds of formula I: and to pharmaceutically acceptable acid addition salts thereof, wherein R-R, R, and Rhave any of the values defined in the specification. The compounds are suitable as imaging tools.

2-phenyl or 2-hetaryl imidazol[1,2-a]pyridine derivatives

The present invention relates to compounds that may be used for binding and imaging tau aggregates and related beta-sheet aggregates including, for example, beta-amyloid aggregates or alpha-synuclein aggregates.

Imidazo[1,2-a]pyridin-7-amine

The present invention relates to compounds of general formula wherein R is hydrogen, halogen, lower alkyl substituted by halogen or lower alkoxy; The compounds are suitable as imaging tool, which will improve diagnosis by identifying potential patients with excess of tau aggregates in the brain, which may be likely to develop Alzheimer's disease.

2-phenylimidazo[1,2-a]pyrimidines as imaging agents

The present application relates to compounds of formula wherein R, R, R, R, and n are defined hereinor to a pharmaceutically active salt thereof. The present compounds are high potential NK-3 receptor antagonists for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, anxiety and attention deficit hyperactivity disorder (ADHD).

Pyrrolidine compounds

The invention provides novel compounds having the general formula (I) wherein R, R, R, R, R, R, R, A, Aand Aare as described herein, compositions including the compounds and methods of using the compounds. These compounds are useful for therapy or prophylaxis in a mammal, and in particular as aldosterone synthase (CYP11B2 or CYP11B1) inhibitors for the treatment or prophylaxis of chronic kidney disease, congestive heart failure, hypertension, primary aldosteronism and Cushing syndrome.

Dihydroquinoline-2-one derivatives

The present invention relates to compounds of formula wherein R, R, R, R, Z, and n are as defined hereinor to a pharmaceutically active salt thereof. Compounds of the invention are high potential NK-3 receptor antagonists for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, anxiety and attention deficit hyperactivity disorder (ADHD).

Pyrrolidine derivatives

Provided are compounds of Formula I,R-L-A-L-R&#x2003;&#x2003;(I),and stereoisomers, tautomers and pharmaceutically acceptable salts thereof, wherein A, L, L, Rand Rare defined herein. The present invention also provides a pharmaceutical composition and methods of using such compounds. The compounds are useful for therapy and/or prophylaxis in a patient, and in particular to inhibitors of Soluble Epoxide Hydrolase (sEH).

Azetidine compounds, compositions and methods of use

The present invention is concerned with isoxazole-pyridine derivatives of formula I wherein X, Rto Rare as described herein. The compounds are active on the GABA A &#x3b1;5 receptor binding site and useful for the treatment of cognitive disorders, such as Alzheimer's disease.

Isoxazolo-pyridine derivatives

Growing community of inventors

Rheinfelden, Germany

Henner Knust